Subscribe
Be the first with the news that moves the market- Zentek (ZEN) announces successful testing of its ZenGUARD antimicrobial technology with over 99.99-per-cent bacterial and viral filtration efficiency
- The ZenGUARD-coated mask fabric demonstrated 86.7-per-cent antiviral effectiveness after 1 hour against H1N1 and 99.7 per cent after 8 hours
- It achieved over 99.99-per-cent reduction in E. coli bacterial growth after just one hour
- The technology may contribute to protecting healthcare professionals and patients in high-risk environments
- Zentek is an IP development and commercialization company focused on next-gen healthcare solutions
- Zentek (ZEN) is unchanged trading at $2.11 per share
Zentek (ZEN) has successfully completed antimicrobial testing on its ZenGUARD-coated mask material.
ZenGUARD achieved over 99.99-per-cent reduction in E. coli bacterial growth after just one hour, while untreated control samples showed a significant increase in bacterial growth.
Additionally, ZenGUARD demonstrated 86.7-per-cent antiviral effectiveness against H1N1 after one hour and 99.7 per cent after 8 hours.
In high-risk indoor settings such as hospitals, where healthcare workers and patients are exposed to dangerous bacteria and viruses daily, the data offers compelling evidence that ZenGUARD-coated mask material can provide additional protection.
The reduction in infectious disease may range from mask acne to potentially preventing significant disease from bacterial or viral infections.
Zentek’s Canadian distribution partner, Southmedic, exclusively distributes ZenGUARD surgical masks for hospitals, clinics, long-term care facilities, nursing homes, and community health care services.
Zentek is an IP development and commercialization company focused on next-gen healthcare solutions.
Zentek (ZEN) is unchanged trading at $2.11 per share as of 1:00 pm EST.
